Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFSNASDAQ:SGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$20.88-7.0%$26.00$14.84▼$29.55$981.36M2.04361,456 shs1.07 million shsSGENSeagen$228.74$228.74$123.77▼$228.96$42.93B0.321.48 million shs86 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions-5.63%-14.25%-9.66%-15.06%+29.56%SGENSeagen0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions1.703 of 5 stars3.50.00.00.01.92.50.6SGENSeagenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.1749.27% UpsideSGENSeagen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BLFS and SGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $30.001/8/2025BLFSBioLife SolutionsNorthland SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $31.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M11.93N/AN/A$7.67 per share2.72SGENSeagen$2.30B18.66N/AN/A$15.10 per share15.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$66.43M-$0.50N/AN/AN/A-38.98%-6.61%-5.54%5/8/2025 (Estimated)SGENSeagen-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/ALatest BLFS and SGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 24BLFSBioLife Solutions-$0.06$0.26+$0.32$0.26$21.73 million$22.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ASGENSeagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.032.781.78SGENSeagenN/A2.672.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%SGENSeagen84.26%Insider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%SGENSeagen25.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.00 million45.37 millionOptionableSGENSeagen3,256187.70 million139.08 millionOptionableBLFS and SGEN HeadlinesRecent News About These CompaniesTrial win sets up new use for Astellas, Seagen's Padcev in bladder cancerMarch 16, 2025 | pharmaphorum.comMerck in "advanced talks" for $40bn Seagen bid; reportMarch 7, 2025 | pharmaphorum.comSeagen posts breast cancer win ahead of Pfizer takeoverFebruary 23, 2025 | pharmaphorum.comIs Merck planning a $30bn-plus move for Seagen?December 6, 2024 | pharmaphorum.comPfizer raises guidance as COVID franchise drives Q3 beatOctober 30, 2024 | seekingalpha.comPfizer Delivers Knockout Q3 Earnings Results, But Investors Are UnimpressedOctober 30, 2024 | seekingalpha.comFranklin Biotechnology Discovery COctober 5, 2024 | morningstar.comSeagen wins Enhertu patent dispute with Daiichi SankyoJuly 20, 2024 | pharmaphorum.comPfizer: Turning The Corner (Rating Upgrade)May 27, 2024 | seekingalpha.comTwo Brothers, a Big Biotech Bet and an $8 Billion PayoutApril 13, 2024 | wsj.comHER2 heats up as Seagen licenses RemeGen ADC for $2.6bnApril 2, 2024 | pharmaphorum.comRon Baron Portfolio Magic: Building Your Financial FutureMarch 20, 2024 | msn.comBailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving marketsMarch 13, 2024 | msn.comPfizer shutting down Seagen's $350M construction project in EverettMarch 1, 2024 | bizjournals.comNeuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk SaysFebruary 24, 2024 | finance.yahoo.comMRNA Feb 2024 64.000 putFebruary 23, 2024 | finance.yahoo.comMRNA Feb 2024 77.000 callFebruary 23, 2024 | finance.yahoo.comPfizer adds bull at Guggenheim on ex-COVID prospectsFebruary 23, 2024 | msn.comMRNA Feb 2024 67.000 putFebruary 22, 2024 | finance.yahoo.comPfizer touts cancer efforts in first Super Bowl commercialFebruary 12, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLFS and SGEN Company DescriptionsBioLife Solutions NASDAQ:BLFS$20.88 -1.56 (-6.95%) Closing price 04:00 PM EasternExtended Trading$20.90 +0.02 (+0.10%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Seagen NASDAQ:SGENSeagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
